TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy.
作者： Hans P. Eikesdal , Stian Knappskog , Turid Aas , Per E. Lønning
DOI: 10.3109/0284186X.2014.922215
关键词: Mastectomy 、 Medicine 、 Breast cancer 、 Fluorouracil 、 Radiation therapy 、 Internal medicine 、 Chemotherapy 、 Axilla 、 Oncology 、 Doxorubicin 、 Neoadjuvant therapy
摘要: AbstractBackground. Before the advent of neoadjuvant chemotherapy, radiotherapy and surgery alone were associated with a high risk uncontrolled locoregional relapses in locally advanced breast cancer (LABC).Material methods. In 1990s we initiated two protocols, where patients LABC given either doxorubicin qW or 5-fluorouracil/mitomycin (FUMI) q3W to shrink tumours prior mastectomy postoperative radiotherapy. Previously, reported TP53 mutation status predict poor response chemotherapy. Here, present long-term survival data, follow-up 20 years (n = 90) 15 FUMI trial 34).Results. Patients TP53-mutated experienced shorter recurrence-free (RFS; 14 vs. 83 months, p < 0.001) overall (OS; 35 90 than wt tumours. Similarily, mutations OS (22 80 0.03) ten...
sci-hub.se 参考文章(29)
Seth M. Steinberg, Sandra M. Swain, Caroline S. Bagley, Marc E. Lippman, David N. Danforth, Margaret N. Wesley, Judith Bader, Richard A. Sorace, Neoadjuvant Chemotherapy in the Combined Modality Approach of Locally Advanced Nonmetastatic Breast Cancer Cancer Research. ,vol. 47, pp. 3889- 3894 ,(1987)
Jennet M. Harvey, Gary M. Clark, C. Kent Osborne, D. Craig Allred, Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer Journal of Clinical Oncology. ,vol. 17, pp. 1474- 1474 ,(1999) , 10.1200/JCO.1999.17.5.1474
C. D. Haagensen, A. P. Stout, CARCINOMA OF THE BREAST: II. CRITERIA OF OPERABILITY. Annals of Surgery. ,vol. 118, pp. 859- 870 ,(1943) , 10.1097/00000658-194311850-00008
R.D. Rubens, P. Armitage, P.J. Winter, D. Tong, J.L. Hayward, Prognosis in inoperable Stage III carcinoma of the breast European Journal of Cancer. ,vol. 13, pp. 805- 811 ,(1977) , 10.1016/0014-2964(77)90134-7
S. Gundersen, H. Høst, E. Lund, E. Hannisdal, S. Kvinnsland, O. Klepp, Chemotherapy with or without high-dose medroxyprogesterone acetate in oestrogen-receptor-negative advanced breast cancer European Journal of Cancer. ,vol. 28, pp. 390- 394 ,(1992) , 10.1016/S0959-8049(05)80060-7
Turid Aas, Anne-Lise Børresen, Stephanie Geisler, Birgitte Smith-Sørensen, Hilde Johnsen, Jan E. Varhaug, Lars A. Akslen, Per E. Lønning, Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients Nature Medicine. ,vol. 2, pp. 811- 814 ,(1996) , 10.1038/NM0796-811
R.D. Rubens, Sheila Sexton, D. Tong, P.J. Winter, R.K. Knight, J.L. Hayward, Combined chemotherapy and radiotherapy for locally advanced breast cancer European Journal of Cancer (1965). ,vol. 16, pp. 351- 356 ,(1980) , 10.1016/0014-2964(80)90352-7
John Bedwinek, Venkata Rao, Carlos Perez, Stage III and localized stage IV breast cancer: irradiation alone vs irradiation plus surgery International Journal of Radiation Oncology Biology Physics. ,vol. 8, pp. 31- 36 ,(1981) , 10.1016/0360-3016(81)90612-X
Gabriel N. Hortobagyi, F. C. Ames, A. U. Buzdar, S. W. Kau, M. D. McNeese, D. Paulus, V. Hug, F. A. Holmes, M. M. Romsdahl, G. Fraschini, C. M. McBride, R. G. Martin, E. Montague, Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer. ,vol. 62, pp. 2507- 2516 ,(1988) , 10.1002/1097-0142(19881215)62:12<2507::AID-CNCR2820621210>3.0.CO;2-D
T. Thorsen, Occupied and unoccupied oestradiol receptor in human breast tumour cytosol. Journal of Steroid Biochemistry. ,vol. 13, pp. 405- 408 ,(1980) , 10.1016/0022-4731(80)90346-5